{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:23:48Z","timestamp":1785281028907,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with SSc. The aim of this study was to explore the effect of nintedanib on cardiomyopathy associated with systemic sclerosis (SSc).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty consecutively hospitalized patients with SSc-ILD were enrolled and prospectively followed. The rate of change at 6\u2009months in cardiac magnetic resonance (CMR) parametric mapping, including myocardial extracellular volume, was primarily evaluated. Other endpoints included changes in CMR functional parameters, echocardiographic parameters, modified Rodnan skin score, serum biomarkers and pulmonary function test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nintedanib was administered in 10 patients, whereas the other 10 were treated without nintedanib or watched, according to ILD severity and progression. Baseline values of CMR parametric mapping were not different between the two groups. The rate of change at 6\u2009months in myocardial extracellular volume was highly different, almost divergent, between the nintedanib group and the control group (\u22121.62% vs +2.00%, P\u2009=\u20090.0001). Among other endpoints, the change in right ventricular ejection fraction was significantly different between the two groups (P\u2009=\u20090.02), with a preferential change in the nintedanib group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc. The anti-fibrotic effect of nintedanib might not be limited to the lung.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac674","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T16:17:54Z","timestamp":1669911474000},"page":"2550-2555","source":"Crossref","is-referenced-by-count":22,"title":["Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8082-1009","authenticated-orcid":false,"given":"Keita","family":"Ninagawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2023-6585","authenticated-orcid":false,"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satonori","family":"Tsuneta","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Ishizaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hisada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-534X","authenticated-orcid":false,"given":"Michihito","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-341X","authenticated-orcid":false,"given":"Yuichiro","family":"Fujieda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi M","family":"Ito","sequence":"additional","affiliation":[{"name":"Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"2023070511441261000_keac674-B1","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023070511441261000_keac674-B2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070511441261000_keac674-B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/23971983211053246","article-title":"Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data-driven, consensus-based WSF\/HFA definition","volume":"7","author":"Bruni","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"2023070511441261000_keac674-B4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2023070511441261000_keac674-B5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2023070511441261000_keac674-B6","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023070511441261000_keac674-B7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cvr\/cvy186","article-title":"Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension","volume":"115","author":"Rol","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2023070511441261000_keac674-B8","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.phrs.2021.105605","article-title":"Repurposing Nintedanib for pathological cardiac remodeling and dysfunction","volume":"169","author":"Umbarkar","year":"2021","journal-title":"Pharmacol Res"},{"key":"2023070511441261000_keac674-B9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023070511441261000_keac674-B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2023070511441261000_keac674-B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023070511441261000_keac674-B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12968-016-0313-7","article-title":"Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis","volume":"18","author":"Diao","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023070511441261000_keac674-B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1532-429X-16-21","article-title":"Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis \u2013 a clinical study using myocardial T1-mapping and extracellular volume quantification","volume":"16","author":"Ntusi","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023070511441261000_keac674-B14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.41308","article-title":"Cardiac intravoxel incoherent motion diffusion-weighted magnetic resonance imaging with T1 mapping to assess myocardial perfusion and fibrosis in systemic sclerosis: association with cardiac events from a prospective cohort study","volume":"72","author":"Terrier","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023070511441261000_keac674-B15","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/rheumatology\/keaa742","article-title":"Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis","volume":"60","author":"Dumitru","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023070511441261000_keac674-B16","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac120","article-title":"Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study","author":"Knight","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023070511441261000_keac674-B17","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1136\/heartjnl-2019-315560","article-title":"Myocardial fibrosis: why image, how to image and clinical implications","volume":"105","author":"Bing","year":"2019","journal-title":"Heart"},{"key":"2023070511441261000_keac674-B18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/rheumatology\/kew488","article-title":"Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis","volume":"56","author":"Bissell","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2023070511441261000_keac674-B19","doi-asserted-by":"crossref","first-page":"8884442","DOI":"10.1155\/2020\/8884442","article-title":"Clinical outcomes of myocarditis after moderate-dose steroid therapy in systemic sclerosis: a pilot study","volume":"2020","author":"Pussadhamma","year":"2020","journal-title":"Int J Rheumatol"},{"key":"2023070511441261000_keac674-B20","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/annrheumdis-2019-215486","article-title":"Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study","volume":"78","author":"Valentini","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac674\/47881797\/keac674.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/7\/2550\/50821465\/keac674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/7\/2550\/50821465\/keac674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:09:46Z","timestamp":1688576986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/7\/2550\/6865025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,12,2]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac674","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,12,2]]}}}